Skip to content
Clinical Trials – home

Pancreas Powder: A Comprehensive Guide for Patients

2 / 4
trials open to patients / all trials
7+
Countries

In short

This article explores the use of Pancreas Powder, also known as pancreatin or pancreatic enzyme replacement therapy (PERT), in clinical trials for various digestive disorders. These trials aim to assess the effectiveness and acceptability of different formulations of Pancreas Powder in treating conditions such as cystic fibrosis, pancreatic exocrine insufficiency, and complications following pancreatic surgery.

At a glance

Study Types
Open-label, single-arm, multicenter, randomized controlled trials
Conditions Studied
Cystic fibrosis with pancreatic exocrine insufficiency, unresectable pancreatic cancer with PEI, post-pancreatic surgery PEI
Main Objectives
Evaluate acceptability of new formulations, assess impact on body weight and nutrition, investigate effects on digestive symptoms
Key Endpoints
Changes in body weight, nutritional parameters, quality of life, digestive symptoms, dosage requirements
Dosage Forms
Gastro-resistant capsules, gastro-resistant granules
Study Durations
Ranging from 8 days to 6 months
Patient Age Groups
Adults (18 years and older)
Safety Monitoring
Adverse events, local tolerability, vital signs

What is Pancreas Powder?

Pancreas powder, also known as pancreatin or pancreatic enzyme replacement therapy (PERT), is a medical treatment containing a mixture of digestive enzymes. These enzymes are normally produced by the pancreas and are essential for proper digestion of food. The main components of pancreas powder include:

  • Lipase: helps digest fats
  • Amylase: helps digest carbohydrates
  • Protease: helps digest proteins

Pancreas powder is derived from pig pancreas and is formulated into various pharmaceutical products, such as Creon and Kreon.

Medical Conditions Treated

Pancreas powder is primarily used to treat pancreatic exocrine insufficiency (PEI), a condition where the pancreas doesn't produce enough digestive enzymes. PEI can occur in several medical conditions, including:

  • Cystic fibrosis: A genetic disorder affecting the lungs and digestive system
  • Pancreatic cancer: Particularly in patients with unresectable (inoperable) tumors
  • Chronic pancreatitis: Long-term inflammation of the pancreas
  • After pancreatic surgery: Such as total pancreatectomy (removal of the pancreas)

How Pancreas Powder Works

When taken orally with meals, pancreas powder supplements the digestive enzymes that the body is lacking. This helps in the breakdown and absorption of nutrients from food, particularly fats, proteins, and carbohydrates. The enzymes in pancreas powder are protected by a special coating that allows them to pass through the stomach acid and reach the small intestine, where they become active and aid in digestion.

Dosage and Administration

The dosage of pancreas powder varies depending on the specific product and the patient's condition. Generally, it is taken with every meal and snack. For example:

  • For Creon, doses may range from 10,000 to 75,000 lipase units per meal, depending on the severity of pancreatic insufficiency
  • Some patients may require doses higher than 70,000 units per main meal

It's crucial to follow your doctor's instructions regarding dosage and timing of administration. Typically, pancreas powder should be taken at the beginning of each meal or snack.

Benefits of Pancreas Powder

Pancreas powder can provide several benefits for patients with pancreatic exocrine insufficiency:

  • Improved digestion and absorption of nutrients
  • Weight gain or maintenance in patients experiencing weight loss
  • Reduction in symptoms such as abdominal pain, bloating, and diarrhea
  • Better nutritional status, which may improve overall health and quality of life
  • In cancer patients, it may help improve tolerance to chemotherapy

Potential Side Effects

While pancreas powder is generally well-tolerated, some patients may experience side effects. These can include:

  • Nausea
  • Abdominal discomfort
  • Constipation
  • Allergic reactions (rare)

It's important to discuss any side effects with your healthcare provider. They may adjust your dosage or recommend ways to manage these effects.

Ongoing Research

Several clinical trials are currently underway to further investigate the benefits and optimal use of pancreas powder:

  • A study is evaluating patient acceptability of a new formulation of Creon containing pancreas powder gastro-resistant pellets in patients with cystic fibrosis
  • Another trial is assessing the role of pancreatic enzyme replacement therapy in patients with unresectable pancreatic cancer, looking at its impact on weight, nutritional status, and quality of life
  • Research is also being conducted on the use of pancreas powder in patients who have undergone total pancreatectomy, to determine optimal dosing strategies

These ongoing studies aim to improve treatment strategies and outcomes for patients requiring pancreatic enzyme replacement therapy.

Questions people often ask

Conditions where Pancreas Powder is being studied

Each condition opens its own overview and trial list

Trials with Pancreas Powder

Recruiting trials first

See all 4 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).